TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in DNA methylation level of tumor suppressor gene (ZNF852)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of transient ischemic attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in National Eye Institute Grading Scale (NEI Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent Standing Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Romberg Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-Legged Standing Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KATZ Independence Index in Activities of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of epididymal head echotexture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Emotional Eating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reliability of the oral symptom assessment scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concurrent validity of the OSAS against the EORTC QLQ-OH15
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of use
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physiological arousal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events During Exercise Training
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Percentage of Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Women in labour or delivered within 2 days of intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Vital Signs-ear temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual rate of acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes of nurses in delivering nutritional care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of nurses in delivering nutritional care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy of nurses in delivering nutritional care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of incomplete and missed sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median percentage change in Montgomery-Asberg Depression Mood Rating Scale (MADRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fractured restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of restorations with retention loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life - EuroQuol 5 Dimensions 5 levels (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General Health Questionnaire -Short-Form-12 (SF12)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Freedom from Atrial Fibrillation without antiarrhythmic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Hospitalization rate for congestive heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: DNA yield from esophageal cytology samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the Oncoguard Esophagus (OGE) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of HIRRT
Endpoint domain: Adverse events/effects
Primary endpoint: Number and proportion of patients with detectable ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients with actionable alterations identified in ctDNA analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turn-around time of ctDNA analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain level difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of weaning from vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of surgical infection site
Endpoint domain: Adverse events/effects
Primary endpoint: serum level of Neutrophil gelatinase-associated lipocalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complex Attention Domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Sentinel lymph nodes detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Family Environment Survey (FES)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Revised Dyadic Adjustment Scale (RDAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived Employment Barriers Scale (PEBS)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Employment Hope Scale (EHS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Breastfeeding efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge levels towards breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quantification of erythema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quantification of pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin damage prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in frequency of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence and incidence of long term sequelae of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean itching severity score at the baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of the mean Itching Severity Scale (ISS) at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline mean of the pruritus severity score on the Visual Analog Scale at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetration aspiration scale (PAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of scores of peeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Speech Outcome
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Tolerability of Donafenib in Combination With KN046
Endpoint domain: Adverse events/effects
Primary endpoint: Severe Hypoglycemia events
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetic Ketoacidosis events
Endpoint domain: Adverse events/effects
Primary endpoint: Delta of 95th percentile of free acceleration norm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MMP-9 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Completing Intended Procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parental combusted tobacco quit rate
Endpoint domain: Mortality/survival
Primary endpoint: Dynamic Cerebral Autoregulation Parameter: Phase Difference (PD) in Degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Neurocognitive Disorders (NCD) events
Endpoint domain: Adverse events/effects
Primary endpoint: allograft dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: allograft volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trans-aortic mean gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of elevated pulsatility of the femoral vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anal incontinence and pelvic organ prolapse symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Female sexual dysfunction symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reliability of PVI changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent items (by weight) ordered by pantry that are labeled green or red
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of pantry clients' selected food that is green or red
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client dietary quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hemodynamic Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in New York Heart Association Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cro-OSDI score measurement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tinetti Balance and Gait Assessment Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with lethal outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Kinematics, kinetics and spatio-temporal parameters of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AECOPD requiring treatment with systemic steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reading test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phoneme deletion test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pneumococcal serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: proportion of responders with platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bladder Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Lymph-Edema grade
Endpoint domain: Adverse events/effects
Primary endpoint: Axial Diffusivity (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative moderate to severe AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Scar thickness at 6 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Patients' Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AAA shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxford Elbow Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of high-risk patients with PAD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ventilation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of acquired pyruvate kinase deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of high risk patients
Endpoint domain: Mortality/survival
Primary endpoint: leucocyte telomere length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin examination from Glogau scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin examination with dermoscopic photoaging scale (DPAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of changes in the chorioretinal atrophic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum hydroxy butyrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in acute phase response proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Favorable functional evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence to standardized handoff intervention (Fidelity)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: New-onset organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Short Physical Performance Battery (SPPB) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Musculoskeletal Function Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parent Acceptance of Intervention - Percent of parents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider Acceptance of Intervention - Percent of providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Facilitator Acceptance of Intervention - Percent of facilitators
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vascular access primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Primary Outcome 1
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Primary Outcome 2
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Primary Outcome 3
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Tolerability of the patch
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of the patch
Endpoint domain: Resource use
Primary endpoint: Initial clinical cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean finger pain during the last 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factors for maintaining or stopping
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Early complications for the mother and fetus
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy root mean square
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of myasthenic patients with NS-NCD related to CNS damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hematological response rate (HeRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Size of the induced papule on the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: modified Rankin Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment success at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients who Complete at least One In-Person Follow-up Outpatient Visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Joint power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diagnostic performance of SPECTRA IMDx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of catheter obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: Microsampling assay of Tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microsampling assay of Sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microsampling assay of Cyclosporine A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in smoke exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving GPPGA pustulation subscore of 0/1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: post-operative opioid analgesic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence and characteristics of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: MTD and recommended Phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: skills assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in myocardial flow reserve (MFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon Monoxide Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurotoxicity events
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-inf of pertuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Certification of receiving OEND programming and naloxone carrying
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: rate of crisis control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical changes in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical changes in salivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in near visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurence of anastomotic leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Carcinoembryonic antigen (CEA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants who Enjoyed VR simulation experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Premorbid cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of neuropsychiatric symptoms in persons with dementia
Endpoint domain: Adverse events/effects
Primary endpoint: LS-ratio cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence in proportion of days covered (PDC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comorbidities (including symptoms, late effects)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of IVL3001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of IVL3001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-1008h of IVL3001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Propecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Propecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-672h of Propecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Clearance (CL/F) of Acetaminophen/Naproxen Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Acetaminophen/Naproxen Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration versus Time Curve from Start of Drug Administration Until Infinity (AUC[0-infinite])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Rating of Patient-Perceived Changes (GRP-PC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Recruitment Potential
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: STRIVE Course Completion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Follow-up Survey Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relevant indexes after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of rejection after drop cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes